AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 64 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $40,000 | -60.4% | 17,202 | -19.3% | 0.00% | – |
| Q4 2021 | $101,000 | -41.3% | 21,314 | -1.8% | 0.00% | – |
| Q3 2021 | $172,000 | -55.8% | 21,698 | -61.2% | 0.00% | – |
| Q2 2021 | $389,000 | -28.1% | 55,861 | -18.2% | 0.00% | -100.0% |
| Q1 2021 | $541,000 | +0.7% | 68,275 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $537,000 | +19.6% | 68,275 | +7.8% | 0.00% | 0.0% |
| Q3 2020 | $449,000 | -23.4% | 63,313 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $586,000 | +208.4% | 63,313 | +55.4% | 0.00% | – |
| Q1 2020 | $190,000 | -38.3% | 40,749 | +1.2% | 0.00% | -100.0% |
| Q4 2019 | $308,000 | -0.6% | 40,283 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $310,000 | +12.3% | 40,283 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $276,000 | +16.0% | 40,283 | +36.2% | 0.00% | – |
| Q1 2019 | $238,000 | +23.3% | 29,576 | +14.7% | 0.00% | – |
| Q4 2018 | $193,000 | -19.2% | 25,794 | +3.4% | 0.00% | – |
| Q3 2018 | $239,000 | -9.5% | 24,949 | 0.0% | 0.00% | -100.0% |
| Q2 2018 | $264,000 | – | 24,949 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 340,679 | $3,604,000 | 1.39% |
| Nantahala Capital Management | 2,213,052 | $23,414,000 | 0.95% |
| SCP Investment, LP | 156,137 | $1,652,000 | 0.82% |
| SPHERA FUNDS MANAGEMENT LTD. | 509,118 | $5,386,000 | 0.74% |
| DELTEC ASSET MANAGEMENT LLC | 151,781 | $1,606,000 | 0.32% |
| Rock Springs Capital Management LP | 650,000 | $6,877,000 | 0.26% |
| Orbimed Advisors | 1,865,524 | $19,737,000 | 0.24% |
| Baker Brothers Advisors | 1,387,872 | $14,684,000 | 0.11% |
| EAM Investors, LLC | 56,726 | $600,000 | 0.10% |
| Stanley-Laman Group, Ltd. | 35,036 | $371,000 | 0.08% |